Leiomyom der Prostata

Ultra-high
b-value diffusion-weighted imaging features of the prostatic leiomyoma-case report. MR images of prostatic leiomyoma. a, b, c Axial, Coronal, and Sagittal High-resolution T2WI images show a well-circumscribed nodule with a capsule (homogeneous low signal intensity) in the bottom of prostatic left inner zone as homogeneous and slightly hypointense signal compared to the muscle (arrows). d On ultra-high b-value DWI (b = 3000 s/mm2), slightly high signal nodule compared to the muscle (arrows) was observed. e On ultra-high b-value DWI apparent diffusion coefficient map, ADC value was 0.817±0.016 × 10−3 mm2/s. f On T1WI MRI with fat suppression (Pre scanned imaging), the homogeneous isointense signal of nodule compared to the muscle was found. g, h, j On Axial contrast T1WI during the arterial phase, the tumor was strongly and homogeneously enhanced. During venous and delay phases, the tumor showed continuous signal increase (arrows). The margin of tumor was clear, and the envelope was not enhanced
bmcmedimaging.biomedcentral.com • CC-by-4.0
Ultra-high
b-value diffusion-weighted imaging features of the prostatic leiomyoma-case report. MR images of prostate cancer. a High-resolution T2WI shows low signal intensity area in the left transition (TZ) and peripheral zone (PZ) (arrows). b On ultra-high b-value DWI (b = 3000 s/mm2), left-side lesions were observed as significantly higher signal nodules (arrows). c On ultra-high b-value DWI (b = 3000 s/mm2) ADC map, ADC value of the left-side lesion was 0.517 ± 0.015 × 10−3 mm2/s (arrows). d On axial contrast T1WI during the arterial phase, the tumor was enhanced strongly and non-homogeneously (arrows). e, f On axial contrast T1WI during venous and delay phases, the tumor was enhanced strongly and non-homogeneously (continuous signal increase, arrows). The margin of tumor was not clear, and there was no envelope
bmcmedimaging.biomedcentral.com • CC-by-4.0
Lizenz: CC BY-SA 4.0

Leiomyom der Prostata

Tumoren der Prostata Radiopaedia • CC-by-nc-sa 3.0 • de

The World Health Organization (WHO) classification of prostate tumors is a commonly used classification system for prostate tumors. The current version was published in 2016 as part of the  WHO Classification of Tumors of the Urinary System and Male Genital Organs  and replaces the previous classification from 2004:

Classification

Epithelial tumors
Glandular neoplasms
  • acinar adenocarcinoma
    • atrophic
    • pseudohyperplastic
    • microcystic
    • foamy gland
    • mucinous
    • signet ring-like cell
    • pleomorphic giant cell
    • sarcomatoid
  • prostatic intraepithelial neoplasia – high grade
  • intraductal carcinoma
  • ductal adenocarcinoma
    • cribriform
    • papillary
    • solid
  • urothelial carcinoma
Squamous neoplasms
  • adenosquamous carcinoma
  • squamous cell carcinoma
  • basal cell carcinoma
Neuroendocrine tumors
  • adenocarcinoma with neuroendocrine differentiation
  • well-differentiated neuroendocrine tumor
  • small cell neuroendocrine carcinoma
  • large cell neuroendocrine carcinoma
Mesenchymal tumors
Haematolymphoid tumors
  • diffuse large B-cell lymphoma
  • chronic lymphocytic leukemia/small lymphocytic lymphoma
  • follicular lymphoma
  • mantle cell lymphoma
  • acute myeloid leukemia
  • B lymphoblastic leukemia/lymphoma
Miscellaneous tumors
  • cystadenoma
  • nephroblastoma
  • rhabdoid tumor
  • germ cell tumor
  • clear cell adenocarcinoma
  • melanoma
  • paraganglioma
  • neuroblastoma
Metastatic tumors
 
Tumor of the seminal vesicles
Epithelial tumors
  • adenocarcinoma
  • squamous cell carcinoma
Mixed epithelial and stromal tumors
  • cystadenoma
Mesenchymal tumors
  • leiomyoma
  • schwannoma
  • mammary-type myofibroblastoma
  • gastrointestinal stromal tumor, NOS
  • leiomyosarcoma
  • angiosarcoma
  • liposarcoma
  • solitary fibrous tumor
  • hemangiopericytoma
Miscellaneous tumors
  • choriocarcinoma
  • seminoma
  • well-differentiated neuroendocrine tumor/carcinoid tumor
  • lymphomas
  • Ewing sarcoma
Metastatic tumors

Changes from prior versions

Modifications to the Gleason grading system were incorporated into the new version among those:

  • cribriform glands and glomeruloid glands should be graded as Gleason 4
  • grading of mucinous carcinoma of the prostate should be according to the growth pattern
New entities and variants

Newly introduced entities include:

  • intraductal carcinoma

Newly introduced variants include:

  • microcystic adenocarcinoma
  • pleomorphic giant cell adenocarcinoma
  • large cell neuroendocrine carcinoma
Leiomyom Radiopaedia • CC-by-nc-sa 3.0 • de

Leiomyoma is a benign smooth muscle (myometrial) tumor, most commonly found in the uterus.

Classification

Leiomyoma is classified by location:

See also

Siehe auch:
Assoziationen und Differentialdiagnosen zu Leiomyom der Prostata:
Leiomyom
 
Wikipedia • CC BY-SA 3.0